ACROSS Global Alliance (ACROSS) held its inaugural Executive Committee meeting in Moscow to launch the latest disruptive company to hit the Biomedical arena.
ACROSS is the first truly global, agile CRO alliance. Offering cost effective, cutting edge innovative solutions for small / medium pharmaceutical and biotech companies as well as public health institutes and non-governmental organizations, ACROSS is the latest player on the global field of clinical trials.
The Executive Committee meeting brought together executives from 12 member companies to finalize the arrangements for positioning ACROSS within the global clinical trial marketplace. The foundation of the global alliance is based primarily on existing solid working relationships between its member companies, and whose executives have a depth and breadth of experience to rival their colleagues in big pharma / CROs.
Operating to a single set of global SOPs and aligning with TransCelerate’s Clinical QMS Framework, ACROSS offers its clients’ high quality study delivery, a single global contract along with the ease of single points of contact throughout the life cycle of the client’s project.
Synergy’s CSO and ACROSS Chairman, Steven Bukvic, who has been instrumental in establishing ACROSS commented: “ACROSS sets out to disrupt the norms of traditional global clinical trial delivery. Listening to and understanding clients’ needs, implementing agile risk-based approaches to project management and operations, as well as adopting innovative technologies to initiate and deliver clinical trials with both speed and professionalism, ACROSS delivers a clear competitive advantage to our clients.”